The estimated Net Worth of Charles Albright is at least $2.73 million dollars as of 15 December 2020. Charles Albright owns over 10,000 units of Editas Medicine Inc stock worth over $131,948 and over the last 8 years he sold EDIT stock worth over $601,530. In addition, he makes $1,996,320 as Executive Vice President et Chief Scientific Officer at Editas Medicine Inc.
Charles has made over 13 trades of the Editas Medicine Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of EDIT stock worth $165,100 on 15 December 2020.
The largest trade he's ever made was exercising 20,000 units of Editas Medicine Inc stock on 7 December 2020 worth over $330,200. On average, Charles trades about 5,538 units every 49 days since 2016. As of 15 December 2020 he still owns at least 34,907 units of Editas Medicine Inc stock.
You can see the complete history of Charles Albright stock trades at the bottom of the page.
Dr. Charles Albright Ph.D. serves as Executive Vice President, Chief Scientific Officer of the Company. Dr. Albright has served as our Chief Scientific Officer since August 2016 and our Executive Vice President and Chief Scientific Officer since August 2019. Prior to joining our company, Dr. Albright served in a variety of roles at Bristol-Myers Squibb Company, a biopharmaceutical company, from January 2004 to August 2016, serving most recently as the Vice President, Genetically Defined Diseases and Genomics. Dr. Albright received his B.S. in chemical engineering and a Ph.D. in biology from the Massachusetts Institute of Technology.
As the Executive Vice President et Chief Scientific Officer of Editas Medicine Inc, the total compensation of Charles Albright at Editas Medicine Inc is $1,996,320. There are 1 executives at Editas Medicine Inc getting paid more, with Cynthia Collins having the highest compensation of $14,489,700.
Charles Albright is 62, he's been the Executive Vice President et Chief Scientific Officer of Editas Medicine Inc since 2019. There are 4 older and 12 younger executives at Editas Medicine Inc. The oldest executive at Editas Medicine Inc is Dr. George McDonald Church Ph.D., 67, who is the Co-Founder & Scientific Advisory Board Member.
Charles's mailing address filed with the SEC is C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE, MA, 02141.
Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr et Kevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine Inc executives and other stock owners filed with the SEC include: